Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
Bd has confirmed reports that the above referenced lots of product may exhibit reduced levels of vancomycin. this may result in two scenarios: - breakthrough growth of vancomycin susceptible enterococcus species control organisms and/or patient isolates on bd bbl vancomycin screen agaror - reduced inhibition of normal flora on all other media types listed above.